The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site.
J. T. M. L. Ribeiro
No relevant relationships to disclose
S. M. Ali
No relevant relationships to disclose
L. Correia
No relevant relationships to disclose
I. M. V. D. Luis
No relevant relationships to disclose
M. Matias
No relevant relationships to disclose
T. Amaral
No relevant relationships to disclose
A. A. F. G. Quintela
Consultant or Advisory Role - Sanofi
K. Leitzel
No relevant relationships to disclose
A. Lipton
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Genentech; Novartis
Research Funding - Monogram Biosciences; Novartis; Wilex
Expert Testimony - Novartis
L. Costa
Consultant or Advisory Role - Amgen; Novartis; Pfizer; Roche